The New England journal of medicine, 2021-02, Vol.384 (7), p.599-609
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Avacopan for the Treatment of ANCA-Associated Vasculitis
- Ist Teil von
- The New England journal of medicine, 2021-02, Vol.384 (7), p.599-609
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The C5a receptor inhibitor avacopan was superior to a tapering schedule of prednisone with respect to remission of ANCA-associated vasculitis at 52 weeks. There were fewer glucocorticoid-associated adverse events in the avacopan group than in the prednisone group, and serious infections did not differ substantially between the two groups.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2023386Titel-ID: cdi_proquest_journals_2490689826
- Format
- –
- Schlagworte
- Administration, Oral, Adverse events, Aniline Compounds - adverse effects, Aniline Compounds - therapeutic use, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy, Antineutrophil cytoplasmic antibodies, Azathioprine, Azathioprine - administration & dosage, Confidence intervals, Creatinine, Cyclophosphamide, Cyclophosphamide - administration & dosage, Double-Blind Method, Drug dosages, Drug Therapy, Combination, Female, Glucocorticoids, Glucocorticoids - administration & dosage, Glucocorticoids - adverse effects, Humans, Immunosuppressive Agents - administration & dosage, Immunotherapy, Kaplan-Meier Estimate, Male, Middle Aged, Monoclonal antibodies, Nipecotic Acids - adverse effects, Nipecotic Acids - therapeutic use, Patients, Prednisone, Prednisone - administration & dosage, Prednisone - adverse effects, Quality of life, Receptor, Anaphylatoxin C5a - antagonists & inhibitors, Recurrence, Remission, Remission Induction, Rituximab, Rituximab - administration & dosage, Vasculitis